Article
Aastrom Biosciences Inc. announced that it has received a Phase I Small Business Innovation Research Grant (SBIR) grant from the National Institutes of Health National Cancer Institute to develop an immunotherapeutic treatment of malignant melanoma using its AastromReplicell System cell production technology.